On March 4, 2025, NovaBay Pharmaceuticals engaged Lucid Capital Markets for financial advisory services to explore potential business combinations, especially if stockholder approval for liquidation is not obtained. The agreement includes fees totaling up to $1.65 million for successful transactions and advisory services.